Bonnie and Ken Shockey encourage cancer patients to research Low Dose Naltrexone

Low Dose Naltrexone (LDN) was not originally intended to be a cancer treatment but one local couple encourages everyone with cancer to do their research on this drug.

Bonnie and Ken Shockey both use LDN, but for very different reasons. Bonnie takes the drug to treat multiple sclerosis (MS), but Ken began taking it when he was diagnosed with prostate cancer.

Both Ken and Bonnie have had positive results with the drug and hope one day it will be added to the list of options for treating different cancers.

In laboratory studies, LDN stopped the growth of new cancer cells, but did not kill the cancer.

Started with MS

Bonnie was diagnosed with MS in 2007 and was on a traditional Federal Food and Drug Adminstration approved treatment, until having a severe allergic reaction to the protein in the drug.

Shockey started researching at her neurologists suggestion and came across LDN as a possible treatment for MS. She started taking LDN in April of 2009, seeing results after just five days.

It literally reversed some of the MS symptoms I had had for several decades, she said.

Kens diagnosis

In 2010, Ken was diagnosed with an aggressive, advanced form of prostate cancer, but showed no symptoms. His rating reached an 8 on the 10-point Gleason scale the scale used to determine the severity of prostate cancer.

Continue reading here:
Bonnie and Ken Shockey encourage cancer patients to research Low Dose Naltrexone